Topline results of RETHINK-ALZ (NCT04994483), which randomized 804 people with mild to moderate Alzheimer’s disease, were originally reported in November 2024, and topline results from REFOCUS-ALZ ...
SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the ...
Amid desperate efforts to find a treatment for the neurodegenerative disease Alzheimer’s, the aducanumab saga continues, as a US Food and Drug Administration panel will determine whether a post-hoc ...
Daratumumab-lenalidomide maintenance significantly increases MRD-negative conversion and reduces progression risk in multiple ...
MedPage Today on MSN
Not all drugs approved for rheumatoid arthritis are equal for pain relief
The same analysis performed on data from the similarly designed SELECT-PsA 1 trial in psoriatic arthritis showed similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback